Today we'll evaluate Instem plc (LON:INS) to determine whether it could have potential as an investment idea. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes ...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we ...

Logos Technologies' ALPHADAS Solution Suite is Market Leading, e-source Data Capture System and Site Automation Software for Managing Early Phase Clinical Studies CONSHOHOCKEN, Pa.--(BUSINESS ...

Instem, a global leader in IT solutions for life sciences, has announced the launch of its new Non-GLP Pathology Module for Provantis, the market share-leading in vivo preclinical study management ...

Most readers would already be aware that Instem's (LON:INS) stock increased significantly by 30% over the past three months. Given that stock prices are usually aligned with a company's financial ...

Szczepan spent the last decade building the regulatory infrastructure for AI-driven preclinical science, not from inside it, but at the table where the rules get made. At Novartis, he led Emerging ...

Instem, a leading provider of to the global early development healthcare market, announced today it has released version 8.4 of its Sequence Retrieval System, also known as “”. is a proven and ...

Instem Continues Powerful Presentation Series Focusing on Their Use of Artificial and Augmented Intelligence Techniques to Improve Drug Development Processes Continuing the presentation series debuted ...

(RTTNews) - IT solutions provider Instem Plc (INS.L) announced Wednesday that it has agreed to be acquired by Ichor Management Ltd., controlled by funds managed by investment firm ARCHIMED, in ...

BOSTON--(BUSINESS WIRE)--Instem, a global leader in SaaS solutions for life sciences R&D, today announced the official opening of its new global headquarters in Boston, Massachusetts, strategically ...

BOSTON & STAFFORDSHIRE, England, April 17, 2025--(BUSINESS WIRE)--Following the FDA’s recent announcement expanding flexibility in preclinical submission evidence, Instem is reaffirming its role as ...